Skip to content

Early Noninvasive Positive Pressure Ventilation in Children With Status Asthmaticus

Safety and Efficacy of Early Initiation of Noninvasive Positive Pressure Ventilation in Pediatric Patients Admitted With Status Asthmaticus

Status
Withdrawn
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01188473
Enrollment
0
Registered
2010-08-25
Start date
2009-01-31
Completion date
2010-01-31
Last updated
2014-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Status Asthmaticus

Keywords

Status Asthmaticus, Noninvasive Positive Pressure Ventilation, Asthma in Children

Brief summary

Status asthmaticus is recognized as a common cause of morbidity in children in the United States. In recent years, hospitalization rates have reached an all time high. This study will evaluate the safety, tolerability and clinical benefit of adding Noninvasive Positive Pressure Ventilation (NPPV)to regular care in children with moderate to moderately severe status asthmaticus.

Detailed description

Status asthmaticus is defined as severe asthma that fails to respond to inhaled short acting β agonists (SABA), oral or intravenous steroids, and oxygen, leading to hospital admission for further management (1). In 2004, asthma exacerbations led to 3% (198,000) of all hospitalizations and 2.5 deaths per 1 million populations in the 0-17 year age group (2). This prospective, unblinded, randomized controlled, pilot clinical trial will compare NPPV plus standard of care versus standard of care alone in children admitted for status asthmaticus. NPPV refers to the delivery of pressurized gas through an external interface such as a nasal or oronasal mask, connected to a pressure targeted ventilator. In other words, it provides ventilator support without the use of an endotracheal tube. This study will investigate the safety, tolerability and efficacy of early initiation of non-invasive NPPV in pediatric patients admitted with status asthmaticus.

Interventions

OTHERNPPV plus standard of care

Patients in the NPPV group were fitted with a nasal mask with gel seals (Comfortgel Masks, Respironics) and placed on the BiPAP Machine (Vision Bipap, Respironics). To optimize patient cooperation, the mask was initially applied manually to the patient's face. After a short adaptation period, it was firmly applied on the face by head straps to minimize air leak without causing skin injury. Pressures were initially set low for comfort and acceptance while being placed on the machine. The inspiratory positive airway pressure (IPAP) was gradually increased to 8 cm H2O in order to achieve a tidal volume of 6-9 ml/kg and the end expiratory positive airway pressure (EPAP) to 5 cm H 2O. These settings remained unchanged throughout the study period.

Sponsors

Southern Illinois University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* children, 1- 18 years of age, with a known history of asthma admitted to the PICU at St John's Children's Hospital with status asthmaticus * clinical asthma score (CAS) between 3 - 8 after receiving one dose of systemic steroid, 1 hour of continuous albuterol (SABA), and 3 doses of ipratropium bromide * written informed consent from the patient's parent or legal guardian

Exclusion criteria

* no previous history of asthma, * absence of airway protective reflexes, * absence of respiratory drive, * excessive oral secretions, * need for emergent intubation as determined by the attending physician, * facial or airway anomaly or injury precluding the use of tight fitting mask

Design outcomes

Primary

MeasureTime frameDescription
clinical asthma score (CAS)initiation, 2 hours, 4-8 hours, 12-16 hours and 24 hours after initiationclinical evaluations such as wheezing, degree of air exchange, respiratory rate, I&E ratio, retractions

Secondary

MeasureTime frameDescription
being able to wear the maskinitiation, 2 hours, 4-8 hours, 12-16 hours and 24 hours after initiationPatient is able to keep the mask on for 24 hours.
transcutaneous oxygen saturationinitiation, 2 hours, 4-8 hours, 12-16 hours and 24 hours after initiation
heart rateinitiation, 2 hours, 4-8 hours, 12-16 hours and 24 hours after initiationdetermined by heart monitor
supplemental oxygeninitiation, 2 hours, 4-8 hours, 12-16 hours and 24 hours after initiation
NPPV related side effectsinitiation, 2 hours, 4-8 hours, 12-16 hours and 24 hours after initiationNPPV related side effects could be minor including nasal bridge pain and skin irritation, gastric insufflations, sinus and ear pain, and dry eyes
mental statusinitiation, 2 hours, 4-8 hours, 12-16 hours and 24 hours after initiationobservation of activity level, agitation, etc.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026